| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 69.67B | 64.90B | 64.11B | 61.59B | 50.53B |
| Gross Profit | 22.24B | 21.16B | 20.73B | 19.70B | 16.36B |
| EBITDA | 12.94B | 10.84B | 10.25B | 10.27B | 9.71B |
| Net Income | 7.68B | 7.26B | 6.87B | 6.88B | 5.91B |
Balance Sheet | |||||
| Total Assets | 65.39B | 55.93B | 51.25B | 47.26B | 43.18B |
| Cash, Cash Equivalents and Short-Term Investments | 11.48B | 5.01B | 9.05B | 7.89B | 8.17B |
| Total Debt | 8.18B | 4.12B | 3.15B | 3.33B | 3.51B |
| Total Liabilities | 33.15B | 26.76B | 24.79B | 24.52B | 23.08B |
| Stockholders Equity | 31.20B | 28.29B | 25.69B | 22.11B | 19.53B |
Cash Flow | |||||
| Free Cash Flow | 10.87B | 8.61B | 9.00B | 8.82B | 8.40B |
| Operating Cash Flow | 11.47B | 9.13B | 9.52B | 9.54B | 8.98B |
| Investing Cash Flow | -2.02B | -7.06B | -2.62B | -4.26B | -4.31B |
| Financing Cash Flow | -2.95B | -6.06B | -5.65B | -5.31B | -4.93B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $75.32B | 23.10 | 32.85% | 2.58% | 4.62% | 1.06% | |
79 Outperform | $40.20B | 19.31 | 14.50% | 1.46% | 7.44% | -4.57% | |
77 Outperform | $166.40B | 22.36 | 25.35% | 2.25% | 6.58% | 1.19% | |
71 Outperform | $274.96B | 26.33 | 35.26% | 2.21% | 4.51% | 21.89% | |
67 Neutral | $27.06B | 17.53 | 15.81% | 2.78% | -1.97% | 48.61% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
At its annual general meeting on January 28, 2026, Accenture plc obtained shareholder approval to amend and restate its 2010 Share Incentive Plan, adding authorization for an additional 7 million shares and extending the plan’s term to December 12, 2035, thereby reinforcing the company’s capacity to use equity-based compensation as a tool for talent retention and long-term incentive alignment. At the same meeting, shareholders also approved the full slate of director nominees, endorsed on a non-binding basis the compensation of named executive officers, ratified KPMG LLP as independent auditor and authorized the audit committee to set its remuneration, and granted the board various authorities under Irish law to issue shares, opt out of pre-emption rights, and determine the price range for re-allotment of treasury shares, collectively strengthening the board’s financial and capital management flexibility.
The most recent analyst rating on (ACN) stock is a Buy with a $313.00 price target. To see the full list of analyst forecasts on Accenture stock, see the ACN Stock Forecast page.